

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: March 1, 2001, 16:18:25 ; Search time 64.32 Seconds
(without alignments)
15.417 Million cell updates/sec

Title: US-09-331-631A-33

Perfect score: 77
Sequence: 1 CXXXXXXCXXXXXXXXXXXXCXXCXXC 29

Scoring table: BLOSUM62DX
Gapop 10.0 , Gapext 0.5

Searched: 268485 seqs, 34193795 residues

Total number of hits satisfying chosen parameters: 268485

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%
Listing first 45 summaries

Database :

1: /SIDSL/gcgdata/geneseq/geneseq/AA1980.DAT:*
2: /SIDSL/gcgdata/geneseq/geneseq/AA1981.DAT:*
3: /SIDSL/gcgdata/geneseq/geneseq/AA1982.DAT:*
4: /SIDSL/gcgdata/geneseq/geneseq/AA1983.DAT:*
5: /SIDSL/gcgdata/geneseq/geneseq/AA1984.DAT:*
6: /SIDSL/gcgdata/geneseq/geneseq/AA1985.DAT:*
7: /SIDSL/gcgdata/geneseq/geneseq/AA1986.DAT:*
8: /SIDSL/gcgdata/geneseq/geneseq/AA1987.DAT:*
9: /SIDSL/gcgdata/geneseq/geneseq/AA1988.DAT:*
10: /SIDSL/gcgdata/geneseq/geneseq/AA1989.DAT:*
11: /SIDSL/gcgdata/geneseq/geneseq/AA1990.DAT:*
12: /SIDSL/gcgdata/geneseq/geneseq/AA1991.DAT:*
13: /SIDSL/gcgdata/geneseq/geneseq/AA1992.DAT:*
14: /SIDSL/gcgdata/geneseq/geneseq/AA1993.DAT:*
15: /SIDSL/gcgdata/geneseq/geneseq/AA1994.DAT:*
16: /SIDSL/gcgdata/geneseq/geneseq/AA1995.DAT:*
17: /SIDSL/gcgdata/geneseq/geneseq/AA1996.DAT:*
18: /SIDSL/gcgdata/geneseq/geneseq/AA1997.DAT:*
19: /SIDSL/gcgdata/geneseq/geneseq/AA1998.DAT:*
20: /SIDSL/gcgdata/geneseq/geneseq/AA1999.DAT:*
21: /SIDSL/gcgdata/geneseq/geneseq/AA2000.DAT:*

pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARYS

Result No.	Score	Query Match	Length	DB ID	Description
1	77	100.0	66	21	Y64780 Human 5' EST relat
2	77	100.0	625	19	W62830 Macadamia integrif
3	77	100.0	666	19	W62828 Macadamia integrif
4	77	100.0	666	19	W62829 Macadamia integrif
5	68	88.3	31	21	Y70731 Wnt antagonist pro
6	68	88.3	44	17	R98208 Nucleotide used in
7	68	88.3	44	21	Y64770 Human 5' EST relat
8	68	88.3	73	20	Y35935 Extended human sec
9	68	88.3	76	21	Y69209 A mouse WDMN-2 pro
10	68	88.3	93	20	Y69209 Amino acid sequenc
11	68	88.3	93	20	Y61614 Human secreted pro
12	68	88.3	93	20	Y36211 Human secreted pro

13	68	88.3	124	19	W56732
14	68	88.3	125	12	R13329
15	68	88.3	125	19	W81779
16	58	88.3	150	8	P70058
17	68	88.3	169	20	Y60558
18	68	88.3	233	21	Y74791
19	68	88.3	297	18	W15761
20	68	88.3	405	19	W33737
21	68	88.3	509	14	R38210
22	68	88.3	529	14	R38209
23	68	88.3	621	21	Y67309
24	68	88.3	680	14	R34445
25	68	88.3	680	19	W49015
26	68	88.3	741	17	Y16462
27	68	88.3	908	21	Y54055
28	68	88.3	910	17	R91737
29	68	88.3	912	21	Y54057
30	68	88.3	1058	15	R54843
31	68	88.3	1058	17	R91734
32	68	88.3	1210	21	Y50616
33	68	88.3	1214	21	Y79152
34	68	88.3	1292	20	Y02425
35	68	88.3	1298	20	Y02423
36	68	88.3	1308	15	R54841
37	68	88.3	1308	17	R91733
38	68	88.3	1342	12	R13833
39	68	88.3	1342	17	R88453
40	68	88.3	1342	19	W69406
41	68	88.3	1342	20	Y16594
42	68	88.3	1343	12	R12608
43	68	88.3	2476	20	W67738
44	68	88.3	2594	16	W14748
45	68	88.3	2813	7	P60053

ALIGNMENTS

RESULT 1	
ID Y64780	standard; Protein; 66 AA.
XX	
AC Y64780;	
XX	
DT 01-FEB-2000	(first entry)
XX	
DE Human 5' EST related polypeptide SEQ ID NO:941.	
XX	
KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;	
KW gene therapy; chromosome mapping; upstream regulatory sequence;	
KW forensic; location; development; protein synthesis; stability;	
KW regulation; Identification.	
XX	
OS Homo sapiens.	
XX	
PN W0953051-A2.	
XX	
PD 21-OCT-1999.	
XX	
PF 09-APR-1999;	99MO-IB00712.
XX	
PR 09-APR-1998;	98US-0057719.
PR 28-APR-1998;	98US-0069047.
XX	
PA (GEST) GENSET.	
XX	
PI Dumas Mline Edwards J, Duclert A, Giordano J;	
XX	
DR WPI: 2000-038446/03.	
DR N-PSDB; Z42394.	
XX	
PT Novel secreted protein 5' expressed sequence tag sequences used in	
diagnostic, forensic, gene therapy, and chromosome mapping procedures	

Nucellus specific
HE4 epididymis-spe
Human HE4 protein.
Human epidermal gr
Human normal blad
Neisseria meningit
Cotton fibrous tis
Epidermal growth f
LD203DA EGF recept
LD102D3 Apal EGF f
Epidermal growth f
Sequence encoded b
Human KAL protein.
Human von Willebra
Amino acid sequenc
HERA-Ig fusion pro
Amino acid sequenc
HER4 with alternat
Receptor tyrosine
Human EGF receptor
Mouse protein kin
Human epidermal gr
Human epidermal gr
HER4. Homo sapien
Receptor tyrosine
HER-3 epithelial g
erbB-3 polypeptide
erbB-3 glycoprotei
erbB-3 protein enc
EGFR-R erbB-3 clon
p19 p105 zona pell
IgG-Fc binding pro
Sequence of von Wt


```

RESULT      4
W62829      ID W62829 standard; Protein; 666 AA.
XX
AC W62829;
XX
XX 27-OCT-1998 (first entry)
XX
DE Macadamia integrifolia antimicrobial protein.
XX
KM antimicrobial protein; infestation; control.
XX
OS Macadamia integrifolia.
XX
FH Key Location/Qualifiers
FT Peptide 1..28 /note="signal peptide"
FT Protein 29..666 /note="mature protein"
XX
PN W09827805-A1.
XX
PD 02-JUL-1998.
XX
PF 22-DEC-1997; 97MO-AU00874.
XX
PR 20-DEC-1996; 96AU-0004275.
XX
PA (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.
XX
PI Bower NI, Goulter KC, Green JL, Manners JM, Marcus JP;
XX
DR WPI: 1998-377279/32.
XX
DR N-PSDB; V42311.
XX
PT Novel anti-microbial protein from e.g. Macadamia integrifolia -
XX
PT useful for controlling microbial infestations of plants or mammals
XX
PS Claim 1; Page 39-41; 96pp; English.
XX
CC The sequence is that of an antimicrobial protein which can
XX
CC be used to control microbial infestations in plants and mammalian
XX
CC animals.
XX
SQ Sequence 666 AA;

Query Match 100.0%; Score 77; DB 19; Length 666;
Best Local Similarity 20.7%; Pred. No. 2e+02;
Matches 6; Conservative 23; Mismatches 0; Indels 0; Gaps 0;

OY 1 CXXCXXCXXCXXCXXCXXCXXCXXCXXCXXC 29
DB 82 cqgcqrrcrqgsqpsrqqyqqrckelc 110

RESULT      5
Y70731      ID Y70731 standard; protein; 31 AA.
XX
AC Y70731;
XX
XX 24-JUL-2000 (first entry)
XX
DE Wnt antagonist protein consensus sequence-1.
XX
KM Wnt antagonist; contraceptive; contraceptive vaccine; oocyte development;
XX
KM female primate contraception; oocyte viability.
XX
OS Synthetic.
XX
SQ

```

```

FH Key Location/Qualifiers
FT Misc-difference 2
FT /label= Unknown
FT /note="Xaa may be 9 amino acids in length; some
FT amino acids may be absent"
FT Misc-difference 4
FT /label= Unknown
FT /note="Xaa may be 42 amino acids in length; some
FT amino acids may be absent"
FT Misc-difference 14
FT /label= Unknown
FT Misc-difference 15
FT /label= Unknown
FT Misc-difference 16
FT /label= Unknown
FT Misc-difference 17
FT /label= Unknown
FT Misc-difference 18
FT /label= Unknown
FT Misc-difference 19
FT /label= Unknown
FT Misc-difference 21
FT /label= Unknown
FT /label= Unknown
FT /note="Xaa may be 10 amino acids in length; some
FT amino acids may be absent"
FT Misc-difference 23
FT /label= Unknown
FT Misc-difference 24
FT /label= Unknown
FT Misc-difference 25
FT /label= Unknown
FT Misc-difference 27
FT /label= Unknown
FT /note="Xaa may be 7 amino acids in length; some
FT amino acids may be absent"
FT Misc-difference 29
FT /label= Unknown
FT /note="Xaa may be 27 amino acids in length; some
FT amino acids may be absent"
FT Misc-difference 31
FT /label= Unknown
FT /note="Xaa may be 13 amino acids in length; some
FT amino acids may be absent"
XX
XX W0200021555-A1.
XX
PD 20-APR-2000.
XX
PF 13-OCT-1999; 99MO-US23640.
XX
PR 15-OCT-1998; 98US-0104355.
XX
PA (HARD ) HARVARD COLLEGE.
XX
XX McMahon AP, Parr BA, Vaino S;
XX
XX WPI: 2000-317845/27.
XX
DR
XX
XX Contraceptive composition for inhibiting oocyte development in a female
XX primate comprises a wnt polypeptide antagonist -
XX
XX Claim 12; Page 44; 57pp; English.
XX
XX The patent discloses a method of female primate contraception comprising
XX administering an antagonist of a wnt polypeptide, inhibiting oocyte
XX development. Wnt polypeptides are useful for promotive maturation of an
XX immature oocyte. Wnt polypeptides are also useful for increasing the
XX number of mature oocytes and to enhance oocyte viability. The present
XX peptide is a consensus sequence of Wnt antagonist which inhibits the
XX physiological activity of a wnt polypeptide. Antagonistic polypeptides
XX may contain a cysteine-rich domain.
XX
XX Sequence 31 AA:
XX

```



```

XX AC Y35935;
XX DT 13-SEP-1999 (first entry)
XX DE Extended human secreted protein sequence, SEQ ID NO. 184.
XX KM Secreted protein; human; cytokine; cellular proliferation; cell movement;
XX KM cellular differentiation; immune system regulator; anti-inflammatory;
XX KM haematopoiesis regulator; tissue growth regulator; tumour inhibitor;
XX KM reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;
XX OS genetic disease.
XX OS Homo sapiens.
XX PN MO9931236-A2.
XX PD 24-JUN-1999.
XX PF 17-DEC-1998; 98WO-1B02122.
XX PR 10-AUG-1998; 98US-0096116.
XX PR 17-DEC-1997; 97US-0069957.
XX PR 09-FEB-1998; 98US-0074121.
XX PR 13-APR-1998; 98US-0081563.
XX PA (GEST ) GENSET.
XX PI Bougueleret L, Duclert A, Dumas Mline Edwards J;
XX DR WPI; 1999-385906/32.
XX DR N-PSDB; X97619.
XX PT New isolated human secreted proteins
XX PS Claim 9; Page 215-216; 516pp; English.
XX XX This sequence is encoded by an extended human secreted protein coding
XX CC sequence of the invention. The secreted proteins can be used in treating
XX CC or controlling a variety of human conditions. The secreted proteins may
XX CC act as cytokines or may affect cellular proliferation or differentiation
XX CC or may act as immune system regulators, haematopoiesis regulators, tissue
XX CC growth regulators, regulators of reproductive hormones or cell movement
XX CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or
XX CC tumour inhibition activity. The DNAs can be used in forensic procedures
XX CC to identify individuals or in diagnostic procedures to identify
XX CC individuals having genetic diseases resulting from abnormal expression of
XX CC the genes corresponding to the extended cDNAs. They are also useful for
XX CC constructing a high resolution map of the human chromosomes. They can
XX CC also be used for gene therapy to control or treat genetic diseases.
XX SQ Sequence 73 AA:

```

Query Match 88.3%; Score 68; DB 20; Length 73;
 Best Local Similarity 17.9%; Pred. No. 1e+02;
 Matches 5; Conservative 23; Mismatches 0; Indels 0; Gaps 0;

QY 2 XXCXXXCXNXXXXXXXXXXCXNXXC 29
 Db 42 dlcjhscfckcetnkcscatcgnic 69

RESULT 9
 Y68907
 ID Y68907 standard; Protein; 76 AA.
 AC Y68907;
 XX
 DT 16-MAY-2000 (first entry)
 DE A mouse WDM-2 protein (homologous to TANGO-175).
 XX

```

KM KM TANGO-175; proteinase; metastasis; inflammation; cancer; inflammation;
KM KM bone marrow accessory cell; hematopoietic stem cell growth;
KM KM hematopoietic disorder; genetic lesion; WDM-2.
XX OS Mus sp.
XX PN MO200006699-A1.
XX PD 10-FEB-2000.
XX PF 29-JUL-1999; 99WO-US17289.
XX PR 29-JUL-1998; 98US-0124538.
XX PA (MILL-) MILLENIUM BIOTHERAPEUTICS INC.
XX PI McCarthy SA;
XX DR WPI; 2000-183117/16.
XX DR N-PSDB; Z60804.
XX PT Novel human and murine TANGO-175 and murine WDM-2 nucleic acids and
XX PT proteins useful for treatment and diagnosis of cancer, inflammation and
XX PT hematopoietic disorders
XX PS Example 3; Fig 3; 134pp; English.
XX CC The present sequence represents mouse WDM-2, which has homology to
XX CC TANGO-175. TANGO-175 is related to several proteins in the four
XX CC disulphide core family. Human TANGO-175 has activities similar to that
XX CC of anti-leukoprotease and WDM-1 and may therefore have a role similar
XX CC to these proteins by inhibiting proteinases associated with metastasis.
XX CC The protein may play a role in regulating inflammation and also in the
XX CC growth of hematopoietic stem cells by neutralizing proteinases produced
XX CC by bone marrow accessory cells. TANGO-175 is therefore useful in
XX CC treatment and diagnosis of cancer, inflammation and hematopoietic
XX CC disorders. Primers and probes, which hybridize to human TANGO-175
XX CC nucleic acid molecules and antibodies against human TANGO-175 protein,
XX CC are useful for detecting the presence of the nucleic acid molecule or
XX CC protein in a sample. The proteins and nucleic acids can be used to screen
XX CC drugs or compounds, which modulate TANGO-175 activity or expression, to
XX CC detect genetic lesions and to modulate TANGO-175 activity.
XX SQ Sequence 76 AA:

```

Query Match 88.3%; Score 68; DB 21; Length 76;
 Best Local Similarity 17.9%; Pred. No. 1e+02;
 Matches 5; Conservative 23; Mismatches 0; Indels 0; Gaps 0;

QY 2 XXCXXXCXNXXXXXXXXXXCXNXXC 29
 Db 44 gicvdqsgdscpgmkkcscnscghvc 71

RESULT 10
 Y69209
 ID Y69209 standard; Protein; 92 AA.
 AC Y69209;
 XX
 DT 30-MAY-2000 (first entry)
 DE Amino acid sequence of honey bee venom PK3.101 protein.
 XX
 XX Protein PK3.101; honey bee; venom; interleukin-8; IL-8; receptor;
 XX CXCR1; CXCR2; cyclooxygenase; lipoxigenase; phospholipase; protease;
 XX inflammatory disease; gene therapy; cancer; autoimmune disease; pain;
 XX chemokine imbalance; rheumatoid arthritis; multiple sclerosis;
 XX psoriasis; systemic lupus erythematosus; Crohn's disease; vasculitis;
 XX scleroderma; metastatic cancer; Alzheimer's disease; wound healing;
 XX aging process; antigen.
 XX

```

OS  Apis mellifera.
XX
FH  Key      Location/Qualifiers
FT  Peptide  1..19
FT          /note= "Signal peptide"
FT  Region   20..34
FT          /note= "this region contains 5 CGX repeats"
XX
XX  GB2341389-A.
XX
XX  15-MAR-2000.
XX
XX  13-SEP-1999: 99GB-0021605.
XX
XX  14-SEP-1998: 98US-0100172.
XX
XX  (PANP-) PAN PACIFIC PHARM INC.
XX
XX  Chi X, Lu Y;
XX
XX  WPI: 2000-185368/17.
XX  N-PSDB: 261247.
XX
XX  Isolated nucleic acids encoding the bee venom protein PX3.101 useful
PT  for treating autoimmune and inflammatory disorders such as rheumatoid
PT  arthritis.
XX
XX  Claim 2: Flg 3A-B: 83pp; English.
XX
XX  The present sequence represents the protein PX3.101, which is a honey
CC  bee venom isolated Apis mellifera. PX3.101 inhibits the binding of
CC  Interleukin-8 (IL-8) to its receptor (e.g. CXCR1 and CXCR2) and
CC  inhibits a variety of enzymes (e.g. cyclooxygenases, lipoxigenases,
CC  phospholipases and proteases) associated with inflammatory diseases.
CC  The nucleic acids may be used for the recombinant production of
CC  PX3.101 proteins either in vivo (as part of a gene therapy protocol)
CC  or in vitro (as a fermentation culture). The nucleic acids may also
CC  be used as probes to identify similar sequences in samples. The PX3.101
CC  protein may be used for the treatment of inflammatory diseases, cancers,
CC  autoimmune diseases, pain and/or diseases associated with chemokine
CC  (especially IL-8) imbalances such as rheumatoid arthritis, multiple
CC  sclerosis, psoriasis, systemic lupus erythematosus (SLE), Crohn's
CC  disease, vasculitis, scleroderma, metastatic cancer and Alzheimer's
CC  disease in humans. It is also disclosed that the proteins may be used
CC  to accelerate wound healing, reduce several aging processes and protect
CC  against ultraviolet light. The proteins may also be used as antigens in
CC  the production of antibodies specific for PX3.101. The antibodies may
CC  be used as diagnostic agents to detect PX3.101 protein in samples and
CC  to down regulate PX3.101 activity.
XX
XX  Sequence 92 AA:
SQ

```

Query Match 88.3%; Score 68; DB 21; Length 92;
 Best Local Similarity 17.9%; Pred. No. 1.3e+02;
 Matches 5; Conservative 23; Mismatches 0; Indels 0; Gaps 0;

```

OY  2 XXXCXXCXXXXXXXXXXXXXXXXXXCXXCXXC 29
    ::::::::::::::::::::::|
DB  44 srodcgrcfcpnvvpkplckikcapgc 71

```

RESULT 11
 Y36164
 ID Y36164 standard; protein: 93 AA.
 AC Y36164;
 XX
 DT 23-SEP-1999 (first entry)
 XX
 DE Human secreted protein #36.
 XX
 KW Secreted protein; human; cytosstatic; thrombotic; osteopathic; forensic;

```

KW  diagnostic; gene therapy; chromosome mapping; secretion vector.
XX
XX  Homo sapiens.
XX
XX  MO9925825-A2.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998: 98WO-IB01862.
XX
XX  04-SEP-1998: 98US-0099273.
XX  13-NOV-1997: 97US-0066677.
XX  17-DEC-1997: 97US-0069957.
XX  09-FEB-1998: 98US-0074121.
XX  13-APR-1998: 98US-0081563.
XX  10-AUG-1998: 98US-0096116.
XX
XX  (GENSET) GENSET.
XX
XX  Bougueleret L, Duclet A, Dumas Milne Edwards J;
XX
XX  WPI: 1999-347472/29.
XX  N-PSDB: X97848.
XX
XX  Extended cDNAs encoding secreted proteins
PT
XX
XX  Example 28: Page 246; 307pp; English.
XX
XX  Y36129-Y36222 represent novel human secreted proteins encoded by the
CC  extended cDNA sequences represented in X97813-X97906. The proteins
CC  of the invention have cytosstatic, thrombotic and osteopathic activity.
CC  The extended cDNAs can be used to express secreted proteins or parts of
CC  them or to obtain antibodies capable of binding to the secreted proteins.
CC  They may also be used in diagnostic, forensic, gene therapy and
CC  chromosome mapping procedures. Uses also include design of expression
CC  vectors and secretion vectors.
XX
XX  Sequence 93 AA:
SQ

```

Query Match 88.3%; Score 68; DB 20; Length 93;
 Best Local Similarity 17.9%; Pred. No. 1.3e+02;
 Matches 5; Conservative 23; Mismatches 0; Indels 0; Gaps 0;

```

OY  2 XXXCXXCXXXXXXXXXXXXXXXXXXCXXCXXC 29
    ::::::::::::::::::::::|
DB  43 enchtltmgdeckgfgccsfcgivc 70

```

RESULT 12
 Y36211
 ID Y36211 standard; protein: 93 AA.
 AC Y36211;
 XX
 DT 23-SEP-1999 (first entry)
 XX
 DE Human secreted protein #83.
 XX
 KW Secreted protein; human; cytosstatic; thrombotic; osteopathic; forensic;
 KW diagnostic; gene therapy; chromosome mapping; secretion vector.
 XX
 OS Homo sapiens.
 XX
 PN MO9925825-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998: 98WO-IB01862.
 XX
 PR 04-SEP-1998: 98US-0099273.
 PR 13-NOV-1997: 97US-0066677.
 PR 17-DEC-1997: 97US-0069957.
 PR 09-FEB-1998: 98US-0074121.
 PR 13-APR-1998: 98US-0081563.
 PR 10-AUG-1998: 98US-0096116.
 PR
 PR 17-DEC-1997: 97US-0069957.

